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Identity 
Other names: BNSP, BSPI, ETA-1, MGC110940, 
Nephropontin, OPN, SPP-1, Uropontin, osteopontin 
HGNC (Hugo): SPP1 
Location: 4q22.1 
Note: Gene type: protein coding. 
DNA/RNA 
Note 
Genes encompassed within a 600 kb region on human 
chromosome 4 encode several noncollageneous bone 
and dentin proteins. They include osteopontin, bone 
sialoprotein, dentin matrix protein I, and dentin 
sialophosphoprotein, all of which have been 
categorized as members of the small integring-binding 
ligand N-linked glycoprotein (SIBLING) family-related 
proteins. The 4 proteins are somewhat similar being 
secreted, sialylated, phosphorylated, and acidic in 
nature. 
Description 
- Osteopontin is encoded by a single copy gene  
 
located on the human chromosome 4; 7 exons. 
- Codon triplets are not interrupted by introns, and 
consequently, exon skipping will not affect the codon 
triplets in the remaining exons. 
- The human gene sequence spans ~9 kb and the open 
reading frame consists of 942 nucleotides from the start 
codon (in exon 2) to the stop codon (in exon 7). 
Transcription 
- The 5'-untranslated region includes exon 1, which 
starts a transcription initiation site (AGC). 
- The 3'-untranslated region consists of the last part of 
exon 7, which includes three potential polyadenylation 
attachment signals (AATAA). 
- Exon 2 encodes the signal peptide and the first two 
amino acids in the mature protein. 
- Exon 3 and 5, the two characteristic Ser-Ser-Glu-Glu 
phosphorylation sequences. 
- Exon 4, the two transglutaminase-reactive glutamine 
residues. 
- Exon 6, the aspartic-rich sequence. 
- Exon 7 is the largest exon encoding approzimately 
half of the proteins including the RGD motif and the 
central thrombin cleavage site. 
 
The gene structure of human osteopontin. Exons are boxed, filled boxes are coding regions and open boxes are untranslated regions. 
SPP1 (secreted phosphoprotein 1) Rodrigues LR 
 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2009; 13(10)  734 
 
Structure of human osteopontin protein indicating selected structural domains. 
 
- There are 3 transcripts for osteopontin splice variants 
that are OPN-a, OPN-b and OPN-c. Alternative 
splicing occurs in a region of the molecule that is 
upstream of the central integrin binding domain and the 
C-terminal CD44 binding domain. OPN-b lacks exon 5 
and OPN-c lacks exon 4. 
- Transcriptional regulation is complex and involves 
multiple pathways including AP-1, Myc, v-Src, 
RunX/CBF, TGF-B/BMPS/Smad/Hox and Wnt/b-
catenin/APC/GSK-3b/Tcf-4. 
Protein 
Note 
Osteopontin serves as a substrate for thrombin and 
matrix metalloproteinases (MMP2, MMP3, MMP7, 
MMP9 and MMP12), can bind to the extracellular 
matrix proteins fibronectin and collagen, and interacts 
with integrins alphaV (beta1, beta2 or beta5) and 
(alpha4, alpha5, alpha8 or alpha9) beta1 surface 
receptors through an Arg-Gly-Asp (RGD) sequence. 
Secreted phosphoprotein 1 (or osteopontin) was 
identified with 7 protein interactions: ITGAV, IGFBP5, 
PDLIM7, CD44, ITGA5, CTNNBL1, SGTA. 
Description 
- Recommended name: osteopontin. 
- Osteopontin is 314 amino acids in length. 
- The molecular weight of osteopontin and associated 
isoforms are measured between 41 and 75 kDa. Post-
translational modifications leading to cell-type and 
condition-specific variations may account for this 
variability in molecular weight. 
- Osteopontin is extremely hydrophilic with a low 
isoelectric point (3.5). 
- It displays an unusual amino acid composition with 
42 serine, 48 aspartic acid and 27 glutaminc acid 
residues. It is important to notice that 27 out of the 42 
serine serine residues are phosphorylated. 
- The predicted secondary structure of osteopontin 
consists of eight alpha-helices and six beta-sheet 
segments. 
- Strutural domains: 
Aspartate domain - amino acid sequence Asp86-Asp89 
- binds hydroxyapatite, 
RGD sequence - amino acid sequence Arg159-Asp159 
- binds alphaVbeta3, alphaVbeta1, alphaVbeta5 and 
alpha5beta1 integrins, 
SVVYGLR sequence - amino acid sequence Ser162-
Arg168 - binds alpha9beta1 and alpha1beta1 integrins, 
Thrombin cleavage site - amino acid sequence Arg168-
Ser169 - displays RGD sequence, 
Calcium binding domain - amino acid sequence 
Asp216-Ser228 - calcium binding, 
Heparin binding domain - amino acid sequence 
Asp290-Ile305 - mediates CD44v3 binding. 
- Post-translational modifications:  
Extensively phosphorylated on clustered serine 
residues, 
N- and O-glycosylated. 
Expression 
Osteopontin is expressed by cells in a variety of tissues, 
including bone, dentin, cementum, hypertrophic 
cartilage, kidney, brain, bone-marrow-derived metrial 
gland cells, vascular tissues and cytotrophoblasts of the 
chorionic villus in the uterus and decidua, ganglia of 
the inner ear, brain cells and specialized epithelia found 
in mammary, salivary, and sweat glands, in bile and 
pancreatic ducts, and in distal renal tubules and in the 
gut, as well as in activated macrophages and 
lymphocytes. 
Cell types which express osteopontin: osteoclasts, 
osteoblasts, kidney, breast and skin epithelial cells, 
nerve cells, vascular smooth muscle cells and 
endothelial cells. Activated immune cells (T-cells, NK 
cells, macrophages and Kupfter cells) also express 
osteopontin. 
Localisation 
It is predominantly secreted but its intracellular form 
has also been described. 
Function 
- Binds tightly to hydroxyapatite. Appears to form an 
integral part of the mineralized matrix. Probably 
important to cell-matrix interaction. 
- Acts as a cytokine involved in enhancing production 
of interferon-gamma and interleukin-12 and reducing 
production of interleukin-10 and is essential in the 
pathway that leads to type I immunity. 
- Participates in bone remodelling, inflammation, 
cancer and immunity to infection disease. 
- Regulates the formation and growth of calcium 
phosphate and oxalate crystals. 
- Is involved in cell attachment and signalling through 
integrins. 
- Is involved in cell attachment and signalling through 
CD44. 
Homology 
The amino acid sequence of osteopontin is nowadays 
available for several species, such as rat, mouse, 
human, pig, rabbit and cow. The referenced 
mammalian osteopontin sequences are identical in 
~33% of the residues, and in addition, many similar 
amino acids are conserved between the sequences. 
Identical residues are scattered in clusters. More 
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specifically, the larger clusters are located in the 
hydrophobic leader sequence (the first 16 residues), in 
a potential site for N-linked glycosylation, and in 
several sites for O-linked glycosylation and 
phosphorylation. A stretch of consecutive aspartic acid 
residues was also found in all species, as well as a cell 
attachment RGD motif almost immediately followed by 
a thrombin cleavage site. 
Implicated in 
Multiple cancers 
Note 
The ability of osteopontin to interact with a diverse 
range of factors including cell surface receptors 
(integrins, CD44), secreted proteases (matrix 
metalloproteinases, urokinase plasminogen activator) 
and growth factor/receptor pathways 
(TGFalpha/EGFR, HGF/MET) is central to its role in 
malignancy. 
Changes in gene expression implies alterations in cell 
properties involved in malignancy such as adhesion, 
migration, invasion, enhanced tumour survival, tumour 
angiogenesis, and metastasis. 
Disease 
Multiple cancers such as breast, thyroid, cervical, 
prostate, lung, gastric, liver and colon. 
At present, it is fully accepted that osteopontin 
expressed by tumour cells alters their malignant 
properties, specifically by affecting their ability to 
grow, invade, and metastatize. However, it is important 
to notice that osteopontin is expressed both in normal 
and malignant tissues. Recent studies suggest that 
osteopontin levels in the blood or tumours of patients 
with cancer may provide useful clinical information on 
patient prognoses. 
Prognosis 
Elevated osteopontin expression correlate with tumour 
invasion, progression or metastasis in multiple cancers 
(thyroid, cervical, breast, prostate, lung, gastric, liver 
and colon). Osteopontin expression is associated with 
disease progression in patients, with higher levels of 
osteopontin produced by cancer cells associated with a 
poorer patient survival. 
Oncogenesis 
Osteopontin is believed to be an effector of activated 
oncogenes functioning to facilitate tumour growth and 
metastasis. 
References 
Butler WT. The nature and significance of osteopontin. 
Connect Tissue Res. 1989;23(2-3):123-36 
Kiefer MC, Bauer DM, Barr PJ. The cDNA and derived amino 
acid sequence for human osteopontin. Nucleic Acids Res. 
1989 Apr 25;17(8):3306 
Brown LF, Berse B, Van de Water L, Papadopoulos-Sergiou A, 
Perruzzi CA, Manseau EJ, Dvorak HF, Senger DR. Expression  
and distribution of osteopontin in human tissues: widespread 
association with luminal epithelial surfaces. Mol Biol Cell. 1992 
Oct;3(10):1169-80 
Denhardt DT, Guo X. Osteopontin: a protein with diverse 
functions. FASEB J. 1993 Dec;7(15):1475-82 
Brown LF, Papadopoulos-Sergiou A, Berse B, Manseau EJ, 
Tognazzi K, Perruzzi CA, Dvorak HF, Senger DR. Osteopontin 
expression and distribution in human carcinomas. Am J Pathol. 
1994 Sep;145(3):610-23 
Hijiya N, Setoguchi M, Matsuura K, Higuchi Y, Akizuki S, 
Yamamoto S. Cloning and characterization of the human 
osteopontin gene and its promoter. Biochem J. 1994 Oct 1;303 
( Pt 1):255-62 
Oates AJ, Barraclough R, Rudland PS. The role of osteopontin 
in tumorigenesis and metastasis. Invasion Metastasis. 
1997;17(1):1-15 
Rittling SR, Novick KE. Osteopontin expression in mammary 
gland development and tumorigenesis. Cell Growth Differ. 
1997 Oct;8(10):1061-9 
Sodek J, Ganss B, McKee MD. Osteopontin. Crit Rev Oral Biol 
Med. 2000;11(3):279-303 
Furger KA, Menon RK, Tuck AB, Bramwell VH, Chambers AF. 
The functional and clinical roles of osteopontin in cancer and 
metastasis. Curr Mol Med. 2001 Nov;1(5):621-32 
Weber GF. The metastasis gene osteopontin: a candidate 
target for cancer therapy. Biochim Biophys Acta. 2001 Dec 
28;1552(2):61-85 
Kim JH, Skates SJ, Uede T, Wong KK, Schorge JO, Feltmate 
CM, Berkowitz RS, Cramer DW, Mok SC. Osteopontin as a 
potential diagnostic biomarker for ovarian cancer. JAMA. 2002 
Apr 3;287(13):1671-9 
Mazzali M, Kipari T, Ophascharoensuk V, Wesson JA, 
Johnson R, Hughes J. Osteopontin--a molecule for all 
seasons. QJM. 2002 Jan;95(1):3-13 
Brakora KA, Lee H, Yusuf R, Sullivan L, Harris A, Colella T, 
Seiden MV. Utility of osteopontin as a biomarker in recurrent 
epithelial ovarian cancer. Gynecol Oncol. 2004 May;93(2):361-
5 
Christensen B, Nielsen MS, Haselmann KF, Petersen TE, 
Sørensen ES. Post-translationally modified residues of native 
human osteopontin are located in clusters: identification of 36 
phosphorylation and five O-glycosylation sites and their 
biological implications. Biochem J. 2005 Aug 15;390(Pt 1):285-
92 
Rodrigues LR, Teixeira JA, Schmitt FL, Paulsson M, Lindmark-
Mänsson H. The role of osteopontin in tumor progression and 
metastasis in breast cancer. Cancer Epidemiol Biomarkers 
Prev. 2007 Jun;16(6):1087-97 
Tuck AB, Chambers AF, Allan AL. Osteopontin overexpression 
in breast cancer: knowledge gained and possible implications 
for clinical management. J Cell Biochem. 2007 Nov 
1;102(4):859-68 
Chakraborty G, Jain S, Kundu GC. Osteopontin promotes 
vascular endothelial growth factor-dependent breast tumor 
growth and angiogenesis via autocrine and paracrine 
mechanisms. Cancer Res. 2008 Jan 1;68(1):152-61 
Hedley BD, Welch DR, Allan AL, Al-Katib W, Dales DW, 
Postenka CO, Casey G, Macdonald IC, Chambers AF. 
Downregulation of osteopontin contributes to metastasis 
suppression by breast cancer metastasis suppressor 1. Int J 
Cancer. 2008 Aug 1;123(3):526-34 
SPP1 (secreted phosphoprotein 1) Rodrigues LR 
 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2009; 13(10)  736 
Mirza M, Shaughnessy E, Hurley JK, Vanpatten KA, Pestano 
GA, He B, Weber GF. Osteopontin-c is a selective marker of 
breast cancer. Int J Cancer. 2008 Feb 15;122(4):889-97 
Partridge CR, He Q, Brun M, Ramos KS. Genetic networks of 
cooperative redox regulation of osteopontin. Matrix Biol. 2008 
Jun;27(5):462-74 
Wai PY, Kuo PC. Osteopontin: regulation in tumor metastasis. 
Cancer Metastasis Rev. 2008 Mar;27(1):103-18 
This article should be referenced as such: 
Rodrigues LR. SPP1 (secreted phosphoprotein 1). Atlas Genet 
Cytogenet Oncol Haematol. 2009; 13(10):733-736. 
